NRAS-mutant melanoma: current challenges and future prospect

References

• RobertCSchachterJLongGVKEYNOTE-006 investigatorsPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• AsciertoPAMcArthurGADrénoBCobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialLancet Oncol20161791248126027480103
   PubMed Web of Science ®Google Scholar
• DhillonSDabrafenib plus trametinib: a review in advanced melanoma with a BRAF (V600) mutationTarget Oncol201611341742827246822
   PubMedGoogle Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• CurtinJAFridlyandJKageshitaTDistinct sets of genetic alterations in melanomaN Engl J Med2005353202135214716291983
   PubMed Web of Science ®Google Scholar
• JakobJABassettRLJrNgCSNRAS mutation status is an independent prognostic factor in metastatic melanomaCancer2012118164014402322180178
   PubMed Web of Science ®Google Scholar
• LeeJHChoiJWKimYSFrequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysisBr J Dermatol2011164477678421166657
   PubMed Web of Science ®Google Scholar
• ThumarJShahbazianDAzizSAJilaveanuLBKlugerHMMEK targeting in N-RAS mutated metastatic melanomaMol Cancer2014134524588908
   PubMed Web of Science ®Google Scholar
• DevittBLiuWSalemiRClinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaPigment Cell Melanoma Res201124466667221615881
   PubMed Web of Science ®Google Scholar
• Diaz-FloresEShannonKTargeting oncogenic RasGenes Dev200721161989199217699748
   PubMedGoogle Scholar
• MalumbresMBarbacidMRAS oncogenes: the first 30 yearsNat Rev Cancer20033645946512778136
   PubMed Web of Science ®Google Scholar
• DaudABastianBCBeyond BRAF in melanomaCurr Top Microbiol Immunol20123559911721826607
   PubMedGoogle Scholar
• FedorenkoIVGibneyGTSmalleyKSNRAS mutant melanoma: biological behavior and future strategies for therapeutic managementOncogene201332253009301823069660
   PubMed Web of Science ®Google Scholar
• DrostenMDhawahirASumEYGenetic analysis of Ras signalling pathways in cell proliferation, migration and survivalEMBO J20102961091110420150892
   PubMed Web of Science ®Google Scholar
• HodisEWatsonIRKryukovGVA landscape of driver mutations in melanomaCell2012150225126322817889
   PubMed Web of Science ®Google Scholar
• AlbinoAPLe StrangeROliffAIFurthMEOldLJTransforming ras genes from human melanoma: a manifestation of tumour heterogeneity?Nature198430859546972
   PubMed Web of Science ®Google Scholar
• MilagreCDhomenNGeyerFCA mouse model of melanoma driven by oncogenic KRASCancer Res201070135549555720516123
   PubMedGoogle Scholar
• BosJLRas oncogenes in human cancer: a reviewCancer Res19894917468246892547513
   PubMed Web of Science ®Google Scholar
• CharbelCFontaineRHMaloufGGNRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic neviJ Invest Dermatol201413441067107424129063
   PubMedGoogle Scholar
• AkslenLAAngeliniSStraumeOBRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survivalJ Invest Dermatol2005125231231716098042
   PubMed Web of Science ®Google Scholar
• EllerhorstJAGreeneVREkmekciogluSClinical correlates of NRAS and BRAF mutations in primary human melanomaClin Cancer Res201117222923520975100
   PubMed Web of Science ®Google Scholar
• OmholtKPlatzAKanterLRingborgUHanssonJNRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progressionClin Cancer Res20039176483648814695152
   PubMed Web of Science ®Google Scholar
• PlatzAEgyhaziSRingborgUHanssonJHuman cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMol Oncol20081439540519383313
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPAKaramouzisMVPapavassiliouAGPost-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targetsNat Rev Drug Discov20076754155517585331
   PubMedGoogle Scholar
• SmalleyKSEisenTGFarnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cellsInt J Cancer2003105216517512673674
   PubMed Web of Science ®Google Scholar
• NiessnerHBeckDSinnbergTThe farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cellsJ Invest Dermatol2011131246847920944654
   PubMed Web of Science ®Google Scholar
• GajewskiTFSalamaAKNiedzwieckiDCancer and Leukemia Group BPhase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)J Transl Med20121024623228035
   PubMed Web of Science ®Google Scholar
• FridayBBAdjeiAAAdvances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapyClin Cancer Res200814234234618223206
   PubMedGoogle Scholar
• RinehartJAdjeiAALorussoPMMulticenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancerJ Clin Oncol200422224456446215483017
   PubMed Web of Science ®Google Scholar
• LoRussoPMKrishnamurthiSSRinehartJJPhase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancersClin Cancer Res20101661924193720215549
   PubMed Web of Science ®Google Scholar
• YehTCMarshVBernatBABiological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitorClin Cancer Res20071351576158317332304
   PubMed Web of Science ®Google Scholar
• AdjeiAACohenRBFranklinWPhase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersJ Clin Oncol200826132139214618390968
   PubMed Web of Science ®Google Scholar
• KirkwoodJMBastholtLRobertCPhase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanomaClin Cancer Res201218255556722048237
   PubMed Web of Science ®Google Scholar
• GuptaALoveSSchuhADOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanomaAnn Oncol201425596897424567366
   PubMed Web of Science ®Google Scholar
• RobertCDummerRGutzmerRSelumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyLancet Oncol201314873374023735514
   PubMed Web of Science ®Google Scholar
• CarvajalRDSchwartzGKMannHSmithINathanPDStudy design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)BMC Cancer20151546726059332
   PubMed Web of Science ®Google Scholar
• CarvajalRDSosmanJAQuevedoJFEffect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialJAMA2014311232397240524938562
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPMETRIC Study GroupImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• GilmartinAGBleamMRGroyAGSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibitionClin Cancer Res2011175989100021245089
   PubMed Web of Science ®Google Scholar
• FalchookGSLewisKDInfanteJRActivity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialLancet Oncol201213878278922805292
   PubMed Web of Science ®Google Scholar
• LongGVStroyakovskiyDGogasHCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaN Engl J Med2014371201877188825265492
   PubMed Web of Science ®Google Scholar
• BendellJCJavleMBekaii-SaabTSA phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorBr J Cancer2017116557558328152546
   PubMed Web of Science ®Google Scholar
• AsciertoPASchadendorfDBerkingCMEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyLancet Oncol201314324925623414587
   PubMed Web of Science ®Google Scholar
• DummerRSchadendorfDAsciertoPABinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialLancet Oncol201718443544528284557
   PubMed Web of Science ®Google Scholar
• LeAPimasertib, a selective oral MEK 1/2 inhibitor, shows clinical activity in cutaneous and uveal metastatic melanoma in the phase I program. EADO congress2012 abstract C06
   Google Scholar
• LarkinJAsciertoPADrénoBCombined vemurafenib and cobimetinib in BRAF-mutated melanomaN Engl J Med2014371201867187625265494
   PubMed Web of Science ®Google Scholar
• SosmanJAKittanehMLolkemaMPJA phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activityJ Clin Oncol201432Suppl 159009
   Google Scholar
• GregerJGEastmanSDZhangVCombinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsMol Cancer Ther201211490992022389471
   PubMed Web of Science ®Google Scholar
• LinCCSuWCYenCJA phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesBr J Cancer2014110102434244024755882
   PubMed Web of Science ®Google Scholar
• VogelCJSmitMAMaddaloGCooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCKPigment Cell Melanoma Res201528330731725728708
   PubMedGoogle Scholar
• VuHLAplinAETargeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanomaMol Cancer Res201412101509151924962318
   PubMed Web of Science ®Google Scholar
• JohnsonDBLovlyCMFlavinMImpact of NRAS mutations for patients with advanced melanoma treated with immune therapiesCancer Immunol Res20153328829525736262
   PubMed Web of Science ®Google Scholar
• JosephRWSullivanRJHarrellRCorrelation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaJ Immunother2012351667222130161
   PubMed Web of Science ®Google Scholar
• JohnsonDBPuzanovITreatment of NRAS-mutant melanomaCurr Treat Options Oncol20151641525796376
   PubMedGoogle Scholar
• ShahabiVWhitneyGHamidOAssessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumabCancer Immunol Immunother201261573373722382362
   PubMed Web of Science ®Google Scholar